Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 85,793 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Terminated Phase 2Phase 3 Interventional Results available

Trial of Hydroxychloroquine In Covid-19 Kinetics

NCT04353271
View directory record Official record
Conditions
Covid 19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

NCT03792971
View directory record Official record
Conditions
Healthy
Interventions
Dextromethorphan HBr, GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

NCT00085371
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
triapine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Results available

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

NCT03256344
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
Interventions
Talimogene Laherparepvec, Atezolizumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Mindfulness

NCT03466164
View directory record Official record
Conditions
Cognitive Change
Interventions
Mindfulness Based Stress Reduction Program
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
22 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 29, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

NCT05420064
View directory record Official record
Conditions
BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation, POLE Gene Mutation, APC Gene Mutation, ATM Gene Mutation, MLH1 Gene Mutation, BARD1 Gene Mutation, MSH2 Gene Mutation, BRIP1 Gene Mutation, MSH6 Gene Mutation, CHEK2 Gene Mutation, PMS2 Gene Mutation, PALB2 Gene Mutation, EPCAM Gene Mutation, RAD51C Gene Mutation, BMPR1A Gene Mutation, RAD51D Gene Mutation, SMAD4, PTEN Gene Mutation, GREM1
Interventions
Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Suspended Phase 1 Interventional

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

NCT03392064
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AMG 119
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 29, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

PopSci CHW4CervixHealth

NCT07336134
View directory record Official record
Conditions
Cervical Cancer, Hpv, Human Papilloma Virus, HPV Infection
Interventions
Evalyn® Brush, Copan Floqswab, CHW4CervicalHealth
Device · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Orthotic Use for Chronic Low Back Pain

NCT00976664
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Shoe orthotic, Shoe Orthotic Wait Group
Device
Lead sponsor
National University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lombard, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Results available

SXC-2023 Cocaine Interaction Study

NCT06343532
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
SXC-2023, SXC-2023 Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preeclampsia Research on Vitamin D, Inflammation, & Depression

NCT03018132
View directory record Official record
Conditions
Pre-Eclampsia, Depression, Inflammation, Vitamin D Deficiency
Interventions
mental health screening, education and referral program
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

COach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation

NCT03142932
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Individualized carbon monoxide (iCO) monitor, COach2Quit smartphone application, Cessation counseling
Device · Other · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 29, 2026, 9:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

NCT05114798
View directory record Official record
Conditions
Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer
Interventions
Time restricted eating, Calorie Restriction
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
45 Years to 70 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Text Message Appointment Reminders

NCT01676337
View directory record Official record
Conditions
Text Messages, Emergencies
Interventions
Text message appointment reminder
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

BMS-599626 in Patients With Advanced Solid Malignancies

NCT00095537
View directory record Official record
Conditions
Cancer, Metastases
Interventions
panHer
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

NCT00608972
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Doxil, Carboplatin, Bevacizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
7
States / cities
Camden, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

NCT00517595
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed and Gemcitabine plus Bevacizumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Waterbury, Connecticut • Augusta, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 29, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

NCT06555939
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Collaborative Care Model, Promoting Resilience in Stress Management
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 9:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia

NCT00415077
View directory record Official record
Conditions
MODERATE AND HIGH MYOPIA
Interventions
PRK, MMC PRK, LASEK
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 29, 2026, 9:51 AM EDT
Terminated Early Phase 1 Interventional

MRI With C13 Pilot Study Prostate Cancer

NCT02450201
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

NCT00509301
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
131-I-chTNT-1/B MAB
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)

NCT00656201
View directory record Official record
Conditions
Infertility
Interventions
Crinone 8% Vaginal Gel, Intramuscular Progesterone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 29, 2026, 9:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

NCT00477412
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 29, 2026, 9:51 AM EDT
Terminated Phase 1 Interventional

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

NCT05083481
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 9:51 AM EDT